InvestorsHub Logo
Followers 20
Posts 5313
Boards Moderated 0
Alias Born 01/04/2012

Re: None

Wednesday, 01/11/2017 9:08:12 PM

Wednesday, January 11, 2017 9:08:12 PM

Post# of 14839
After reading "Rheumatoid Arthritis: The Big 3 And The Future", I am convinced the $350 million Priority Review Voucher is not intended for the ABT-494. The possibilities in their existing pipeline have been knocked down one by one. It has got to be for Libigel. If so, it gives us a good idea of the market potential.

Rheumatoid Arthritis: The Big 3 And The Future
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News